{"id":"cov795","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in conditions characterized by dysregulated immune activation.","oneSentence":"COV795 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:24.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune or inflammatory conditions (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT01451385","phase":"PHASE3","title":"Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2011-09-20","conditions":"Osteoarthritis, Low Back Pain","enrollment":376},{"nctId":"NCT01484652","phase":"PHASE3","title":"Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2011-11","conditions":"Pain, Postoperative, Bunion","enrollment":329}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MNK795"],"phase":"phase_3","status":"active","brandName":"COV795","genericName":"COV795","companyName":"Mallinckrodt","companyId":"mallinckrodt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"COV795 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Autoimmune or inflammatory conditions (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}